{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:53:50Z","timestamp":1791500030547,"version":"4.3.4"},"reference-count":83,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are synthetic peptides that mimic the natural activity of GLP-1, widely known for lowering blood glucose levels and promoting weight reduction. These characteristics make them a valuable tool in managing type 2 diabetes and obesity-related conditions. Recent findings indicate that GLP1-RAs may also offer therapeutic benefits in managing hidradenitis suppurativa (HS), a chronic inflammatory skin disorder closely associated with metabolic abnormalities, including obesity, diabetes, and dyslipidemia. This review explores the potential role of GLP1-RAs in managing HS. Methods: A systematic review was conducted by searching electronic databases, including MEDLINE and Google Scholar, without date limitations. Key search terms included \u201cGLP-1\u201d or \u201cGLP-1 agonists\u201d combined with \u201chidradenitis suppurativa\u201d or \u201cacne inversa\u201d. Inclusion criteria were set for studies reporting on the use of GLP1-RAs as a treatment for HS, with articles discussing theoretical applications excluded. Data synthesis included findings from 25 relevant studies. Results: The analysis revealed that GLP1-RAs, specifically liraglutide and semaglutide, led to significant reductions in weight and systemic inflammation in HS patients. Notably, improvements in lesion severity and quality of life were reported. The anti-inflammatory effects of GLP1-RAs were attributed to the suppression of key inflammatory pathways involving TNF-\u03b1, IL-17, and NF-\u03baB. Conclusions: GLP1-RAs demonstrate significant potential as an adjunct therapy for HS, addressing both the metabolic and inflammatory aspects of the condition. While early results are promising, further research is necessary to determine their long-term efficacy in managing HS.<\/jats:p>","DOI":"10.3390\/jcm13216292","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T04:10:14Z","timestamp":1729570214000},"page":"6292","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4722-8531","authenticated-orcid":false,"given":"Piotr K.","family":"Krajewski","sequence":"first","affiliation":[{"name":"University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4777-4024","authenticated-orcid":false,"given":"Aleksandra","family":"Z\u0142otowska","sequence":"additional","affiliation":[{"name":"University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-6342","authenticated-orcid":false,"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Wroclaw University of Science and Technology, 51-377 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bjd.15233","article-title":"The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide","volume":"177","author":"Jennings","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.medcli.2023.09.018","article-title":"Hidradenitis suppurativa. Hidradenitis supurativa","volume":"162","year":"2024","journal-title":"Med. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/ijd.16892","article-title":"Therapeutic potential of GLP-1 agonists for hidradenitis suppurativa","volume":"62","author":"Henry","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Mintoff, D., Agius, R., Fava, S., and Pace, N.P. (2023). Investigating Adiposity-Related Metabolic Health Phenotypes in Patients with Hidradenitis Suppurativa: A Cross-Sectional Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12144847"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"20406223211055920","DOI":"10.1177\/20406223211055920","article-title":"New perspectives on the treatment of hidradenitis suppurativa","volume":"12","author":"Vilarrasa","year":"2021","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00403-021-02233-y","article-title":"Lifestyle modifications associated with symptom improvement in hidradenitis suppurativa patients","volume":"314","author":"Macklis","year":"2022","journal-title":"Arch. Dermatol. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/RHU.0000000000001949","article-title":"Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis: A Scoping Review","volume":"30","author":"Karacabeyli","year":"2024","journal-title":"J. Clin. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clindermatol.2004.01.001","article-title":"Obesity and dermatology","volume":"22","author":"Scheinfeld","year":"2004","journal-title":"Clin. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamadermatol.2021.1677","article-title":"Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta-regression Analysis","volume":"157","author":"Jfri","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4103\/cjp.cjp_67_21","article-title":"Hidradenitis suppurativa: Disease pathophysiology and sex hormones","volume":"64","author":"Chu","year":"2021","journal-title":"Chin. J. Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Krajewski, P.K., Matusiak, \u0141., von Stebut, E., Schultheis, M., Kirschner, U., Nikolakis, G., and Szepietowski, J.C. (2021). Quality-of-Life Impairment among Patients with Hidradenitis Suppurativa: A Cross-Sectional Study of 1795 Patients. Life, 11.","DOI":"10.3390\/life11010034"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat. Rev. Dis. Primers."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/ijd.14500","article-title":"Hidradenitis suppurativa and metabolic syndrome\u2014Systematic review and adjusted meta-analysis","volume":"58","author":"Phan","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Scala, E., Cacciapuoti, S., Garzorz-Stark, N., Megna, M., Marasca, C., Seiringer, P., Volz, T., Eyerich, K., and Fabbrocini, G. (2021). Hidradenitis Suppurativa: Where We Are and Where We Are Going. Cells, 10.","DOI":"10.3390\/cells10082094"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis","volume":"82","author":"Goldburg","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/CCID.S111019","article-title":"Hidradenitis suppurativa: From pathogenesis to diagnosis and treatment","volume":"10","author":"Napolitano","year":"2017","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ad.2023.06.017","article-title":"Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases. Agonistas del receptor de GLP-1 para el tratamiento de la obesidad en pacientes con dermatosis inmunomediadas","volume":"115","author":"Vilarrasa","year":"2024","journal-title":"Actas Dermosifiliogr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000517017","article-title":"Metabolic Disorders\/Obesity Is a Primary Risk Factor in Hidradenitis Suppurativa: An Immunohistochemical Real-World Approach","volume":"238","author":"Kaleta","year":"2022","journal-title":"Dermatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.23736\/S2784-8671.23.07307-3","article-title":"Irisin, a novel metabolic biomarker in hidradenitis suppurativa: Correlation with clinical responsivity to anti-TNF-\u03b1 therapy","volume":"158","author":"Cacciapuoti","year":"2023","journal-title":"Ital. J. Dermatol. Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","article-title":"Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity","volume":"161","author":"Sartorius","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_24","first-page":"437","article-title":"Body mass index at the onset of hidradenitis suppurativa","volume":"19","author":"Vanlaerhoven","year":"2021","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jdcr.2023.01.035","article-title":"Metabolic endoscopy and a simplified low-carbohydrate-high-dietary fiber template as novel treatments for hidradenitis suppurativa\u2014A case series","volume":"34","author":"Mandour","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jaad.2018.12.070","article-title":"Skin changes in the obese patient","volume":"81","author":"Hirt","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjd.13090","article-title":"Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: A cross-sectional study","volume":"171","author":"Kromann","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2340\/00015555-1800","article-title":"The influence of body weight on the prevalence and severity of hidradenitis suppurativa","volume":"94","author":"Kromann","year":"2014","journal-title":"Acta Derm. Venereol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-48382-5_1","article-title":"The Definition and Prevalence of Obesity and Metabolic Syndrome","volume":"960","author":"Engin","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"adv00471","DOI":"10.2340\/00015555-3830","article-title":"Impact of Bariatric Surgery on Hidradenitis Suppurativa","volume":"101","author":"Canard","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2017.08.042","article-title":"Hidradenitis suppurativa and diabetes mellitus: A systematic review and meta-analysis","volume":"78","author":"Bui","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Abu Rached, N., Gambichler, T., Ocker, L., Dietrich, J.W., Quast, D.R., Sieger, C., Seifert, C., Scheel, C., and Bechara, F.G. (2023). Screening for Diabetes Mellitus in Patients with Hidradenitis Suppurativa-A Monocentric Study in Germany. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076596"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/met.2015.0095","article-title":"Obesity, Oxidative Stress, Adipose Tissue Dysfunction, and the Associated Health Risks: Causes and Therapeutic Strategies","volume":"13","author":"Manna","year":"2015","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Zatterale, F., Longo, M., Naderi, J., Raciti, G.A., Desiderio, A., Miele, C., and Beguinot, F. (2020). Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front. Physiol., 10.","DOI":"10.3389\/fphys.2019.01607"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1172\/JCI200319246","article-title":"Obesity is associated with macrophage accumulation in adipose tissue","volume":"112","author":"Weisberg","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Witte, K., Wolk, K., Witte-H\u00e4ndel, E., Krause, T., Kokolakis, G., and Sabat, R. (2023). Targeting Metabolic Syndrome in Hidradenitis Suppurativa by Phytochemicals as a Potential Complementary Therapeutic Strategy. Nutrients, 15.","DOI":"10.3390\/nu15173797"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/bjd\/ljac107","article-title":"Adipokines as an important link between hidradenitis suppurativa and obesity: A narrative review","volume":"188","author":"Krajewski","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Chait, A., and den Hartigh, L.J. (2020). Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front. Cardiovasc. Med., 7.","DOI":"10.3389\/fcvm.2020.00022"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1210\/en.2009-0543","article-title":"Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I","volume":"150","author":"Boller","year":"2009","journal-title":"Endocrinology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/bjd.17578","article-title":"Substantially reduced life expectancy in patients with hidradenitis suppurativa: A Finnish nationwide registry study","volume":"180","author":"Tiri","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s42255-020-00327-x","article-title":"Metabolic Messengers: Glucagon-like peptide 1","volume":"3","author":"Gribble","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: Similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J. Diabetes Investig."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Pandey, S., Mangmool, S., and Parichatikanond, W. (2023). Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective. Pharmaceuticals, 16.","DOI":"10.3390\/ph16060836"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1124\/jpet.106.100982","article-title":"Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts","volume":"317","author":"Zhao","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nature04410","article-title":"Oscillations of cyclic AMP in hormone-stimulated insulin-secreting beta-cells","volume":"439","author":"Dyachok","year":"2006","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.regpep.2004.10.002","article-title":"Effect of GLP-1 on glucose transport and its cell signalling in human myocytes","volume":"126","author":"Acitores","year":"2005","journal-title":"Regul. Pept."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Finan","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials","volume":"11","author":"Gilbert","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cmdc.201700781","article-title":"Glucagon-Like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes","volume":"13","author":"Cheang","year":"2018","journal-title":"ChemMedChem"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Psilopanagioti, A., Nikou, S., Logotheti, S., Arbi, M., Chartoumpekis, D.V., and Papadaki, H. (2022). Glucagon-like Peptide-1 Receptor in the Human Hypothalamus Is Associated with Body Mass Index and Colocalizes with the Anorexigenic Neuropeptide Nucleobindin-2\/Nesfatin-1. Int. J. Mol. Sci., 23.","DOI":"10.1101\/2022.10.22.513332"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s00125-011-2297-z","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: Diabetes meets dermatology","volume":"54","author":"Drucker","year":"2011","journal-title":"Diabetologia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/2042018814543483","article-title":"Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis","volume":"5","author":"Azar","year":"2014","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1007\/s00125-011-2232-3","article-title":"Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: Lessons from obesity, diabetes and psoriasis","volume":"54","author":"Hogan","year":"2011","journal-title":"Diabetologia"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Hu, Y., Chen, Y., Chen, Z., Zhang, X., Guo, C., Yu, Z., Xu, P., Sun, L., Zhou, X., and Gong, Y. (2022). Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.799560"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1007\/s00018-010-0396-5","article-title":"Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes","volume":"67","author":"Marx","year":"2010","journal-title":"Cell Mol. Life Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/exd.12081","article-title":"Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques","volume":"22","author":"Faurschou","year":"2013","journal-title":"Exp. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., and LeRoith, D. (2023). Glucagon-like peptide-1: A multi-faceted anti-inflammatory agent. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1148209"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Tilinca, M.C., Tiuca, R.A., Burlacu, A., and Varga, A. (2021). A 2021 Update on the Use of Liraglutide in the Modern Treatment of \u2018Diabesity\u2019: A Narrative Review. Medicina, 57.","DOI":"10.3390\/medicina57070669"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/osp4.84","article-title":"Liraglutide for weight management: A critical review of the evidence","volume":"3","author":"Mehta","year":"2017","journal-title":"Obes. Sci. Pract."},{"key":"ref_63","first-page":"53","article-title":"Clinical Impact of Liraglutide as a Treatment of Obesity","volume":"13","author":"Alruwaili","year":"2021","journal-title":"Clin. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.medcli.2023.11.007","article-title":"Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa","volume":"162","author":"Nicolau","year":"2024","journal-title":"Med. Clin."},{"key":"ref_65","first-page":"4800","article-title":"Liraglutide suppresses TNF-\u03b1-induced degradation of extracellular matrix in human chondrocytes: A therapeutic implication in osteoarthritis","volume":"11","author":"Mei","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (MCP-1): An overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4103\/ijd.ijd_594_22","article-title":"Pathogenesis of Hidradenitis Suppurativa: An Immunological Perspective","volume":"68","author":"Verma","year":"2023","journal-title":"Indian J. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/09546634.2019.1708853","article-title":"Liraglutide improved inflammation via mediating IL-23\/Th-17 pathway in obese diabetic mice with psoriasiform skin","volume":"32","author":"Chen","year":"2021","journal-title":"J. Dermatolog Treat."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7570\/jomes20059","article-title":"Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes","volume":"30","author":"Seo","year":"2021","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/bjd\/ljae216","article-title":"Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: Its impact on disease control and quality of life","volume":"191","author":"Lyons","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/1346-8138.15913","article-title":"Pathophysiology of psoriasis: A review","volume":"48","author":"Yamanaka","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12016-016-8535-x","article-title":"The Inflammatory Response in Psoriasis: A Comprehensive Review","volume":"50","author":"Deng","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_74","first-page":"e52099","article-title":"Psoriasis and Metabolic Disorders: A Comprehensive Meta-Analysis of Million Adults Worldwide","volume":"16","author":"Alajroush","year":"2024","journal-title":"Cureus"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"103577","DOI":"10.1016\/j.autrev.2024.103577","article-title":"Global prevalence of obesity in patients with psoriasis: An analysis in the past two decades","volume":"23","author":"Wang","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diabres.2019.03.002","article-title":"Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study","volume":"150","author":"Xu","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.medcli.2023.05.021","article-title":"Effects of liraglutide among patients living with psoriasis and obesity","volume":"161","author":"Nicolau","year":"2023","journal-title":"Med. Clin."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/09546634.2021.1882658","article-title":"Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: A systematic review and meta-analysis of prospective cohort and before-after studies","volume":"33","author":"Chang","year":"2022","journal-title":"J. Dermatolog Treat."},{"key":"ref_80","first-page":"100340","article-title":"Anti-inflammatory benefits of semaglutide: State of the art","volume":"36","author":"Yaribeygi","year":"2024","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_81","first-page":"21-0007","article-title":"Two birds one stone: Semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient","volume":"2021","author":"Costanzo","year":"2021","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_82","first-page":"23-0017","article-title":"Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes","volume":"2023","author":"Malavazos","year":"2023","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diabet.2011.11.004","article-title":"Improvement of psoriasis during exenatide treatment in a patient with diabetes","volume":"38","author":"Buysschaert","year":"2012","journal-title":"Diabetes Metab."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6292\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:17:47Z","timestamp":1760113067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/21\/6292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":83,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["jcm13216292"],"URL":"https:\/\/doi.org\/10.3390\/jcm13216292","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]}}}